CN104435666B - Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application - Google Patents
Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application Download PDFInfo
- Publication number
- CN104435666B CN104435666B CN201410635579.9A CN201410635579A CN104435666B CN 104435666 B CN104435666 B CN 104435666B CN 201410635579 A CN201410635579 A CN 201410635579A CN 104435666 B CN104435666 B CN 104435666B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- extract
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition with functions of loosening bowel relieving constipation, it is characterised in that the raw material containing following parts by weight：20 60 parts of xylo-oligosaccharide powder；15 45 parts of cassia seed extract；8 24 parts of Bitter Orang P.E；11 33 parts of ophiopogon japonicus extract；13 39 parts of glutinous rehmannia extract；13 39 parts of Radix Codonopsis extract.The present invention is using Chinese medical extract as main component, and extract is usually the active ingredient extracted by steps such as dedusting, purification, sterilizations from Chinese medicine material, and compared with Chinese medicine material, bioavilability is higher, drug effect is more preferable, security is more guaranteed.The present invention targetedly selects suitable single or more herbal medicines, and is combined according to certain organizational principle.Wherein the cassia seed dried immature fruit of citron orange has discharge function, and Radix Codonopsis reinforces the spleen to benefit the lung, metaplasia qi and blood, makes enteron aisle transporting strong；The tuber of dwarf lilyturf, radix rehmanniae recen enriching yin increase liquid ease constipation, and xylo-oligosaccharide promotes enterocinesia, while is prebiotics, promotes the breeding of probiotics in enteron aisle.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, more particularly to a kind of Chinese medicine composition with functions of loosening bowel relieving constipation.
Background technology
Constipation is clinical common complicated symptom, rather than a kind of disease, is primarily referred to as that defecation frequency is reduced, excrement amount subtracts
Less, excrement is dry and hard, defecation is laborious etc..Illness rate of the constipation in crowd is up to 27%, but only sub-fraction constipation person can be just
Examine.Constipation can influence the people of each age group.Women is more than male, and old age is more than the blue or green, prime of life.Because the constipation incidence of disease is high, the cause of disease
Complexity, patient are often had manifold vexations, and quality of life can be influenceed when constipation is serious.Constipation patient need to according to constipation weight, the cause of disease and
Type, using complex treatment, including general life treatment, drug therapy, biofeedback training and operative treatment, to recover normal
Defecation physiology.
The traditional Chinese medical science thinks, caused by the main stomach accumulated heat of the constipation cause of disease, depression and stagnation of QI, deficiency of yin-fluid and blood, phlegm stagnancy.Thus, just
A secret disease, is broadly divided into that heat is secret, gas is secret, void is secret and constipation due to endogenous cold four is classified Chinese medical discrimination.Showed with the formula for the treatment of by Chinese herbs constipation
Stage has many patent documents to disclose, as CN101797287A discloses the defaecation Chinese medicine group of a kind of strengthening the spleen and replenishing qi, enriching the blood and moisturizing the intestine
Compound, be mainly made up of the tuber of multiflower knotweed, Radix Angelicae Sinensis, the root of herbaceous peony, the bighead atractylodes rhizome, fructus cannabis, radix pseudostellariae and saline cistanche, have filling liver kidney and benefiting essence-blood,
The effect of clearing heat and cooling blood, and then play a part of relaxing bowel.CN1887334A discloses a kind of drug regimen to relax bowel
Thing, it is right containing plurality of Chinese raw material, such as folium sennae, pockmarks benevolence, Chinese cassia tree, bamboo juice, rheum officinale, saltcake, the coptis, honeysuckle, radix glycyrrhizae
Accumulated heat constipation has preferable therapeutic action.CN103272036A discloses a kind of Chinese medicine composition to relax bowel, containing white
The Chinese medicine materials such as art, Fructus Aurantii, pawpaw, Radix Angelicae Sinensis or Chinese medical extract, especially suitable for treatment the dysfunction of the spleen in transport, yin deficiency intestine-dryness due to consumption of fluid it
Constipation.Also prolonged illness is controlled, due to constipation person of the activity less and caused by causing intestinal motility to slow down.But existing disclosed treatment constipation
Chinese medicine preparation is mostly traditional Chinese medicinal material raw materials, takes inconvenience and potential safety hazard be present.
The content of the invention
The technical problem to be solved in the present invention is to provide it is a kind of with functions of loosening bowel relieving constipation using Chinese medical extract be main
The Chinese medicine composition of composition.
For the above-mentioned purpose, a kind of Chinese medicine composition with functions of loosening bowel relieving constipation of the present invention, contains following parts by weight
Raw material：Xylo-oligosaccharide powder 20-60 parts；Cassia seed extract 15-45 parts；Bitter Orang P.E 8-24 parts；Ophiopogon japonicus extract 11-33
Part；Glutinous rehmannia extract 13-39 parts；Radix Codonopsis extract's 13-39 parts.
Above-mentioned each raw materials market is on sale, as Chinese medical extract is purchased from Xuancheng plant Trade Co., Ltd..
The Chinese medicine composition of the present invention, preferably comprise the raw material of following parts by weight：40 parts of xylo-oligosaccharide powder；Cassia seed extracts
30 parts of thing；16 parts of Bitter Orang P.E；22 parts of ophiopogon japonicus extract；26 parts of glutinous rehmannia extract；26 parts of Radix Codonopsis extract.
The Chinese medicine composition of the present invention, can be the various Chinese medicine preparation forms with or without pharmaceutic adjuvant.
Preferably, the 20-99% of total formulation weight is accounted for containing above-mentioned Chinese medicine material in the preparation containing pharmaceutic adjuvant.
Above-mentioned dosage form can be capsule, pulvis, tablet or granule.
The preparation method of above-mentioned capsule：By above-mentioned each raw material it is well mixed after, add or be added without silica or
Magnesium stearate, filling capsule, is produced.
The preparation method of above-mentioned pulvis：After above-mentioned each raw material is well mixed, pineapple powder, celery powder, apple powder, stone are added
One or more in pomegranate juice powder, cherry powder, tomato meal, jujube powder, carrot meal, orange juice powder, well mixed pack produce.
The preparation method of above-mentioned tablet or granule：Above-mentioned raw materials are well mixed, add microcrystalline cellulose, carboxymethyl forms sediment
Powder sodium, and be granulated with PVP K30, lubricant is then added, tabletting, which is made tablet or is granulated, is made granule.
The invention further relates to the application of above-mentioned Chinese medicine composition, and it can be used for the medicine for preparing treatment constipation.
The invention difference from existing technology is that the present composition is using Chinese medical extract as main component, extraction
Thing is usually the active ingredient extracted by steps such as dedusting, purification, sterilizations from Chinese medicine material, raw compared with Chinese medicine material
Thing availability is higher, drug effect is more preferable, security is more guaranteed.Each rational weight proportion of Chinese medical extract is sent out for optimal drug effect
Wave and play an important role.The present invention is according to state of an illness needs, on dialectical legal basis, the appropriate medicine of compatibility.Provide suitable dose,
Suitable single or more herbal medicines are targetedly selected, and is combined according to certain organizational principle.The wherein cassia seed dried immature fruit of citron orange
There is discharge function, Radix Codonopsis reinforces the spleen to benefit the lung, metaplasia qi and blood, makes enteron aisle transporting strong；The tuber of dwarf lilyturf, radix rehmanniae recen enriching yin increase liquid ease constipation, oligomeric
Xylose promotes enterocinesia, while is prebiotics, promotes the breeding of probiotics in enteron aisle.Proved by testing, Chinese medicine group of the present invention
Compound has good functions of loosening bowel relieving constipation, has the effect of fine to constipation caused by treatment a variety of causes.
Embodiment
Make in more detail with test data, the technical characteristic above-mentioned and other to the present invention and advantage with reference to embodiments
Explanation.
Embodiment 1
The following Chinese medicine material component of precise：
Xylo-oligosaccharide powder 200g；Cassia seed extract 450g；Bitter Orang P.E 80g；Ophiopogon japonicus extract 110g；Glutinous rehmannia is extracted
Thing 390g；Radix Codonopsis extract 370g, altogether 1600g.
After above-mentioned each raw material is well mixed, contain above-mentioned Chinese medicine material 1600g as standard using 4000 capsules, filling glue
Capsule, produce capsule.Instructions of taking, 2 times a day, 2 tablets each time.
Embodiment 2
The following Chinese medicine material component of precise：
Xylo-oligosaccharide powder 600g；Cassia seed extract 150g；Bitter Orang P.E 240g；Ophiopogon japonicus extract 330g；Glutinous rehmannia carries
Take thing 130g；Radix Codonopsis extract 150g, altogether 1600g.
After above-mentioned each raw material is well mixed, pineapple powder 1000g, apple powder 1000g, orange juice powder 1000g, Hu Luo are added
Foretell part 1400g, be well mixed pack, every bag of 3g, fill 2000 bags, take after mixing it with water twice daily, one bag every time.
Embodiment 3
The following Chinese medicine material component of precise：
Xylo-oligosaccharide powder 400g；Cassia seed extract 300g；Bitter Orang P.E 160g；Ophiopogon japonicus extract 220g；Glutinous rehmannia carries
Take thing 260g；Radix Codonopsis extract 260g, altogether 1600g.
Above-mentioned raw materials are well mixed, add microcrystalline cellulose, sodium carboxymethyl starch, and are granulated with PVP K30, then
Lubricant is added, tabletting, every 4000 contain above-mentioned Chinese medicine material 1600g, and instructions of taking, 2 times a day, 2 tablets once.Or make
Granula, pack, every 2000 bags of granules contain above-mentioned Chinese medicine material 1600g, and daily 2 bags are taken, one bag every time.
Embodiment 4
The following Chinese medicine material component of precise：
Xylo-oligosaccharide powder 200g；Cassia seed extract 450g；Bitter Orang P.E 80g；Ophiopogon japonicus extract 110g；Glutinous rehmannia is extracted
Thing 390g；Radix Codonopsis extract 370g, altogether 1600g.
After above-mentioned each raw material is well mixed, magnesium stearate 400g is added, contains above-mentioned Chinese medicine material with 4000 capsules
1600g is standard, filling capsule, produces capsule.Instructions of taking, 2 times a day, 2 tablets each time.
The tested material bowel relaxing functions of test example 1 are tested
1 materials and methods
1.1 samples are made by above-described embodiment.
1.2 experimental animal health cleaning grade Kunming kind female mices 120,18~22g of body weight [it is real to tie up tonneau China by Beijing
The offer of zoo technical Co., Ltd, credit number are provided：SCXK (capital) 2009-0009], wherein 60 are divided into 5 groups, every group 12,
It is a collection of as testing, carry out intestinal motility experiment；Another 60 are divided into 5 groups, every group 12, as experiment two batches, when carrying out defecation
Between, the measure of fecal grains and stool weight.
The recommended dose of 1.3 dose of test things is adult (pressing 60kg batheroom scales) daily 1.6g, equivalent to 0.027g/kgBW
Body weight.Experiment sets 5 times, 10 times, 30 times of human body recommended dose, i.e., daily 0.0.14g/kgBW, 0.27g/kgBW, 0.81g/
KgBW is basic, normal, high three dosage groups.Orally administration once a day, continuous gavage survey indices after 9 days.Mouse stomach body
Product is 0.1mL/10g.Blank control group (0g/kgBW) and model control group (0g/kgBW) are set simultaneously, is replaced with water (sterilization)
Tested material, daily gavage volume and identical with each tested material group.
1.4 instruments and reagent disscting instrument, ruler, gastric perfusion needle, AE100 electronic balances
Active powdered carbon, gum arabic, R-1132 (lomotil 2.5mg/ pieces)
1.5 experimental method
1.5.1 intestinal motility is tested
After continuously giving tested material 9 days, each group mouse fasting can't help water 16 hours.Model control group and three dosage groups fill
Stomach gives compound diphenoxylate (5m g/kgBW), and blank control group is to distilled water.After compound diphenoxylate 0.5 hour, dosage
Group gives the prepared Chinese ink (containing 5% activated carbon, 10% gum arabic) containing corresponding tested material, blank control group and model pair respectively
Prepared Chinese ink gavage is given according to group.After 25 minutes immediately take off cervical vertebra put to death animal, open abdominal cavity separation mesenterium, cut off upper end from pylorus,
Lower end is placed on pallet to the intestinal tube of ileocecus, small intestine gently is pulled into straight line, measurement Length of intestine is " total small intestinal length ".
Ink progradation is calculated as follows：
Ink progradation (%)=prepared Chinese ink promotes length (cm)/total small intestinal length (cm) × 100%
On the premise of Constipated mice is set up, the ink progradation of test sample group mouse is significantly higher than model comparison
Group, you can judge this index result positive.
1.5.2 the measure of mouse defecation time, fecal grains and stool weight
After continuously giving tested material 9 days, each group mouse fasting can't help water 16 hours.Blank control group is to distilled water, model
Control group and three dosage group gavages give compound diphenoxylate (10m g/kgBW), empty after compound diphenoxylate 0.5 hour
White control group and model control group give prepared Chinese ink gavage, and dosage group gives the prepared Chinese ink containing corresponding tested material respectively, and the equal single cage of animal is fed
Support, normal water feed.Since being filled prepared Chinese ink, record in every animal first grain row's melena time and 6 hours and arrange melena grain number
And weight.On the premise of small intestine Constipation Model is set up, first grain row's melena time of given the test agent mouse is considerably shorter than model pair
According to group, you can judge this index result positive.Melena grain number is arranged in 6 hours apparently higher than model control group, can determine that this
Index result is positive.
1.6 data processing
Data processing is carried out with SPSS softwares, using variance analysis.
1.7 result judgement foundations
It is positive that any one of melena grain number and weight result are arranged in 6 hours, while intestinal motility experiment and defecation time are any
Item result is positive, can determine that the tested material bowel relaxing functions results of animal positive.
2 results
Influence of 2.1 tested materials to mouse weight
The original body mass of mouse is more balanced between each group, and the tested material of orally administration various dose is after 9 days, the body of mouse
Each dosage group of two batches experimental animal is focused on compared between model control group, there are no significant for weight differences.I.e. tested material is to mouse
Body weight has no adverse effects.
Influence of 2.2 tested materials to ink progradation
Influence of the tested material of table 1 to ink progradation
From table 1, the tested material of orally administration mouse various dose is after 9 days, model control group and blank control group ratio
Compared with ink progradation significantly reduces (p ＜ 0.01), shows that model is successfully established.0.23g/kgBW dosage groups and model comparison
Group compares, and ink progradation has significant difference (P<0.05)；0.45g/kgBW dosage groups, 1.35g/kgBW dosage groups and model
Control group compares, and ink progradation has significant difference (P<0.01).As a result showing the tested material group of three dosage can improve
Mouse small intestine exercise testing ink progradation.
Influence of 2.3 tested materials to defecation time
Influence of the tested material of table 2 to defecation time
From table 2, the tested material of orally administration mouse various dose is after 9 days, model control group and blank control group ratio
Compared with first grain row's melena time significantly extends (p ＜ 0.01), shows that model is successfully established.1.35g/kgBW dosage groups and model pair
Compare according to group, defecation time has significant difference (P<0.05).As a result show that 1.35g/kgBW dosage groups can shorten mouse defecation
Time.
Influence of 2.4 tested materials to mouse defecation grain number
Influence of the tested material of table 3 to defecation grain number
From table 3, the tested material of orally administration mouse various dose is after 9 days, model control group and blank control group ratio
Compared with row's melena grain number substantially reduces (p ＜ 0.01), shows that model is successfully established.For each dosage group compared with model control group, row is black
Just grain number there are no significant difference (P ＞ 0.05), illustrate that the tested material arranges mouse melena grain number without influence.
Influence of 2.5 tested materials to mouse defecation weight
Influence of the tested material of table 4 to defecation weight
From table 4, the tested material of orally administration mouse various dose is after 9 days, model control group and blank control group ratio
Compared with defecation weight substantially reduces (p ＜ 0.01), shows that model is successfully established.0.23g/kgBW dosage groups, 0.45g/kgBW dosage
For group compared with model control group, defecation weight has significant difference (P<0.05), 1.35g/kgBW dosage groups and model control group
Compare, defecation weight has significant difference (P<0.01) result show 0.23g/kgBW dosage groups, 0.45g/kgBW dosage groups,
1.35g/kgBW dosage groups can increase mouse defecation weight.
3 brief summaries
The tested material of orally administration mouse various dose is after 9 days, and model control group is compared with blank control group, the tested material
0.23g/kgBW dosage groups can improve mouse small intestine exercise testing ink progradation (P<0.05) mouse defecation weight (P, is increased<
0.05)；0.45g/kgBW dosage groups can improve mouse small intestine exercise testing ink progradation (P<0.01) mouse defecation grain, is increased
Number (P<0.05) mouse defecation weight (P, is increased<0.05)；1.35g/kgBW dosage groups can improve mouse small intestine exercise testing ink
Juice propulsion rate (P<0.01) mouse defecation time (P can, be shortened<0.05) mouse defecation grain number (P, is increased<0.01) mouse, is increased
Defecation weight (P<0.01).Tested material has no adverse effects to mouse weight.According to《Health food is examined and assessment technique specification》,
Illustrate that tested material has the function of defaecation.
The bowel relaxing functions human feeding trial of test example 2
1. object and method
1.1 tested material：Capsule, provided by Beijing Recovery Biotechnology Co., Ltd..
1.2 study subject：18-65 year is selected by the principle of voluntariness, constipation subject 100.
1.2.1 diagnostic criteria：Infrequent defecation time lengthening, just matter is dry and hard or involved and abstruse not smooth functional consitipation person for stool.
1.2.2 include this standard
1.2.2.1 defecation frequency reduces or stool hardness enhancer
1.2.2.2 defecate one week and be less than 3 persons
1.2.2.3 without organic constipation person
1.2.2.4 habitual constipation person
1.2.3 exclude this standard：
1.2.3.1 the age is in under-18s or over-65s person, pregnant occasion or women breast-feeding their children, those who are allergic to the health care products.
1.2.3.2 the severe primary disease such as conscience kidney and hemopoietic system is associated with, or there are other adjoint diseases to control
Treatment person, mental patient.
1.2.3.3 inclusive criteria is not met, does not take tested material by regulation, can not judging effect or data, umbra does not ring work(
Effect or security judge.
1.3 control forms：Take own control experimental design.
1.4 taking doses and time：Test-meal group takes capsule 2 tablets each time, and 2 times a day, continuous 15 days, subject was testing
Period cuts out medicine or other health products about relaxing bowel.
1.5 instruments and reagent：MEK-6318K types blood counting instrument (Japan's production), MIDIRON urinates ten analyzers (Germany
Production), automatic clinical chemistry analyzer (U.S.'s production), model RA1000, biochemical reagents box is all provided by Zhong Sheng companies.
2. observation index
It is each before and after experiment to check once.
2.1 ordinary circumstance：
Detailed medical history-taking, understand subject's spirit, sleep, diet, observation main clinic symptoms：Feeling of fullness, abdominal distension, just do
Situations such as tying, be involved and abstruse not smooth.By mild symptoms multiple integral, symptom improvement rate is calculated.
2.2 efficiency observation：
2.2.1 daily defecation frequency：
2.2.2 defecation condition：I-IV levels are divided into according to difficult defecation degree, count integrated value.
I levels (0 point)：Defecation is normal
II levels (1 point)：Only bearing down, sense of discomfort
III level (2 points)：Bearing down, sense of discomfort are obvious, or have just frequency but a difficult defecation and measure it is few, it is less occur suffering from abdominal pain or
Anus burn feeling
IV levels (3 points)：Often occur suffering from abdominal pain or anus burn feeling, influence defecation
2.2.3 fecal character；Fecal character is divided into by I-III levels according to Bristol fecal character classification.
I levels (0 point)：It is smooth and soft as sausage or snake；As sausage, but there is slight crack on its surface；Soft agglomerate, has
Obvious edge (easily discharge)
II levels (1 point)：Sausage shape, but have agglomerate；Loose bulk, edge roughness, as slimy excrement
III level (2 points)：The hard group of separation, as fruit stone (being not easy to discharge)
2.3 safety observations：
2.3.1 blood, urine, feces routine inspection：
Red blood cell count(RBC), hemoglobin, white blood cell count(WBC), routine urinalysis, just routine inspection.
2.3.2 Biochemical Indexes
Seralbumin ALB, total protein TP, darling renal function (glutamic-oxalacetic transaminease AST, glutamic-pyruvic transaminase ALT, urea
UREA, inosine CRE), blood glucose GLU, blood fat (T-CHOL TC, triglycerides TG).
2.3.3 abdominal B-scan ultrasonography, electrocardiogram, x-ray fluoroscopy of chest.
3 bowel movement functions judge：
Effectively：Bowel frequency number substantially increases, and an index integration is decreased obviously in defecation condition and fecal character binomial index,
Difference has conspicuousness.
It is invalid：Defecation frequency is without obvious increase, and defecation condition and fecal character are without significant change.
4. experimental result：
4.1 general status：Constipation subject 100 is observed altogether, is randomly divided into two groups.
Ordinary circumstance compares before 4.2 two groups of observations：
Ordinary circumstance compares (X ± SD) before table 1 is observed
| Packet | Number of cases | Age | Sex | The course of disease | Constipation |
| (example) | (year) | Men and women | (year) | (times/week) | |
| Test-meal group | 50 | 43.16±8.10 | 2327 | 6.39±5.37 | 2.10±0.62 |
4.3 defecation frequencies change：
The defecation frequency of table 2 changes (times/week)
| Number of cases | Before test-meal | After test-meal | Difference | |
| Test-meal group | 50 | 2.12±0.72 | 6.72±3.36 | -4.6±3.18** |
**P<0.01
4.4 defecation conditions change：
The integral of defecation condition of table 3 changes (level)
| Number of cases | Before test-meal | After test-meal | Difference | |
| Test-meal group | 50 | 1.88±0.63 | 0.50±0.58 | 1.38±0.73** |
**P<001
4.5 excrement change in shape：
The excrement shape of table 4 integration change (degree)
| Number of cases | Before test-meal | After test-meal | Difference | |
| Test-meal group | 50 | 1.80±0.49 | 0.56±0.61 | 1.24±0.62** |
**P<0.01
The change of clinical symptoms before and after 4.6 test-meals
The change of clinical symptoms before and after the test-meal of table 5
| Symptom | Effective (example) | Effectively (example) | Invalid (example) | Improvement rate % |
| Observation group | Observation group | Observation group | Observation group | |
| Feeling of fullness | 4 | 15 | 6 | 76.00 |
| Just it is dry and hard | 15 | 26 | 6 | 87.23 |
| It is involved and abstruse not smooth | 19 | 18 | 11 | 77.08 |
4.7 symptom integrals change
The symptom integral of table 6 changes
| Number of cases | Before test-meal | After test-meal | Difference | |
| Test-meal group | 50 | 12.44±4.65 | 5.44±3.88 | -7.00±3.51** |
**P<0.01
4.8 safety indexes detection：
The safety indexes detection of table 7
Indices are in normal range (NR) before and after test-meal.
4.9 abdominal B-scan ultrasonographies, electrocardiogram, x-ray fluoroscopy of chest is in normal range (NR).
5 conclusions：
5.150 constipation subjects take capsule 15 days on request, as a result test-meal group weekly defecation frequency increase by 4.60 ±
3.18 times, fecal character softens 1.24 ± 0.62 degree, and defecation condition improves 1.38 ± 0.73 grades, and it is logical to illustrate that the tested capsule has
Just function.
5.2 tested capsules are to feeling of fullness, just dry and hard, the involved and abstruse symptom such as not smooth has improvement result.
Before and after 5.3 tested capsule test-meals, third turn of hemoglobin, red blood cell, leucocyte, total serum protein, albumin, paddy ammonia
Enzyme, glutamic-oxalacetic transaminease, inosine, urea, blood glucose, blood fat and routine urinalysis, just the Index for examination such as conventional is in normal range (NR), illustrate
Product have no adverse effects to subject's health.
After 5.4 tested capsule test-meals, allergy and other adverse reactions are had no.
Embodiment described above is only that the preferred embodiment of the present invention is described, not to the model of the present invention
Enclose and be defined, on the premise of design spirit of the present invention is not departed from, technical side of the those of ordinary skill in the art to the present invention
The various modifications and improvement that case is made, it all should fall into the protection domain of claims of the present invention determination.
Claims (9)
1. a kind of Chinese medicine composition with functions of loosening bowel relieving constipation, it is characterised in that be made up of the bulk drug of following parts by weight：It is low
Xylan powder 20-60 parts；Cassia seed extract 15-45 parts；Bitter Orang P.E 8-24 parts；Ophiopogon japonicus extract 11-33 parts；Glutinous rehmannia carries
Take thing 13-39 parts；Radix Codonopsis extract's 13-39 parts.
2. Chinese medicine composition according to claim 1, it is characterised in that be made up of the bulk drug of following parts by weight：It is oligomeric
40 parts of xylose powder；30 parts of cassia seed extract；16 parts of Bitter Orang P.E；22 parts of ophiopogon japonicus extract；26 parts of glutinous rehmannia extract；Radix Codonopsis
26 parts of extract.
3. Chinese medicine composition according to claim 1, it is characterised in that：For the various Chinese medicines with or without pharmaceutic adjuvant
Dosage form.
4. Chinese medicine composition according to claim 3, it is characterised in that：Right will in the preparation containing pharmaceutic adjuvant
Bulk drug described in 1 is asked to account for the 20-99% of total formulation weight.
5. Chinese medicine composition according to claim 1, it is characterised in that：The dosage form of the Chinese medicine composition is capsule
Agent, pulvis, tablet or granule.
6. the preparation method of the Chinese medicine composition described in claim 5, it is characterised in that：The dosage form of the Chinese medicine composition
For capsule, its preparation method is after each bulk drug described in claim 1 is well mixed, to add or be added without titanium dioxide
Silicon or magnesium stearate, filling capsule, are produced.
7. the preparation method of the Chinese medicine composition described in claim 5, it is characterised in that：The dosage form of the Chinese medicine composition
For pulvis, its preparation method is after each bulk drug described in claim 1 is well mixed, to add pineapple powder, celery powder, apple
One or more in powder, juice of my pomegranate powder, cherry powder, tomato meal, jujube powder, carrot meal, orange juice powder, it is well mixed pack
Produce.
8. the preparation method of the Chinese medicine composition described in claim 5, it is characterised in that：The dosage form of the Chinese medicine composition
For tablet or granule, its preparation method is after each bulk drug described in claim 1 is well mixed, to add microcrystalline cellulose
Element, sodium carboxymethyl starch, and be granulated with PVP K30, lubricant is then added, tabletting, which is made tablet or is granulated, is made particle
Agent.
9. the application of the Chinese medicine composition described in claim any one of 1-5, it is characterised in that：Use it for preparing treatment constipation
Medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410635579.9A CN104435666B (en) | 2014-11-05 | 2014-11-05 | Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410635579.9A CN104435666B (en) | 2014-11-05 | 2014-11-05 | Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435666A CN104435666A (en) | 2015-03-25 |
| CN104435666B true CN104435666B (en) | 2017-12-01 |
Family
ID=52882927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410635579.9A Active CN104435666B (en) | 2014-11-05 | 2014-11-05 | Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435666B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920180A (en) * | 2016-04-21 | 2016-09-07 | 哈药集团中药二厂 | Health food with efficacy of relaxing bowel and preparation method of health food |
| CN106605914A (en) * | 2016-08-11 | 2017-05-03 | 西安源森生物科技有限公司 | Composition capable of lubricating the intestines, relaxing the bowels, expelling toxin and expelling lead, as well as preparation method thereof |
| CN111437248A (en) * | 2020-03-17 | 2020-07-24 | 东华理工大学 | Intestine-benefiting life-prolonging oral liquid and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103445044A (en) * | 2012-05-30 | 2013-12-18 | 周建强 | Soft capsule for relaxing bowel |
-
2014
- 2014-11-05 CN CN201410635579.9A patent/CN104435666B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103445044A (en) * | 2012-05-30 | 2013-12-18 | 周建强 | Soft capsule for relaxing bowel |
Non-Patent Citations (1)
| Title |
|---|
| 低聚木糖调节BALB/c小鼠肠道菌群及润肠通便作用研究;魏涛等;《安徽农业科学》;20131231;第41卷(第1期);159-160,163页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104435666A (en) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013010383A1 (en) | Intestine-hydrating and laxative drink and preparation method therefor | |
| CN101015603A (en) | Medicine composition with fat-reducing and bowel relaxing functions, preparing process and quality controlling means thereof | |
| CN109010655A (en) | The integration of drinking and medicinal herbs Chinese medicine for preventing and treating hyperuricemia | |
| CN102524639A (en) | Fruit and vegetable fiber chewable tablet with defaecation and health care functions and preparation method thereof | |
| CN102885309A (en) | Chloasma removing healthcare food composite and preparation method thereof | |
| CN104435666B (en) | Chinese medicine composition with functions of loosening bowel relieving constipation and its preparation method and application | |
| CN106689955A (en) | Solid beverage for promoting postpartum rehabilitation and relieving dysmenorrhea | |
| CN108743892A (en) | The preparation method and applications of " Shengyang Yiwei Decoction " side's Chinese medical extract | |
| CN110934971A (en) | Composition with digestion promoting function and preparation method and application thereof | |
| CN111195314A (en) | Traditional Chinese medicine composition for nourishing stomach and promoting digestion and preparation method thereof | |
| CN100594924C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing the same | |
| CN104524416A (en) | Pharmaceutical composition, and use and preparation method of pharmaceutical composition as well as medicine, food and/or health food prepared from pharmaceutical composition | |
| CN112076170A (en) | Tablet with function of relaxing bowels | |
| CN105497111B (en) | Traditional Chinese medicine preparation for promoting lactation and preparation method thereof | |
| CN105920180A (en) | Health food with efficacy of relaxing bowel and preparation method of health food | |
| CN114306424B (en) | Traditional Chinese medicine composition for treating obesity and preparation method and application thereof | |
| CN109999088A (en) | A kind of compound preparation and its application with effect of relaxing bowel | |
| CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
| US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
| CN105396026A (en) | Traditional Chinese medicine preparation containing cistanche deserticola, and preparation method thereof | |
| CN1315411C (en) | Health-care food with functions of relaxing the bowels and beautifying, and its prepn. method | |
| CN109620913B (en) | Composition for preventing and/or treating obesity and hyperglycemia | |
| CN110354196B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104173734B (en) | A kind of pharmaceutical composition for treating IGR and preparation method thereof | |
| CN108815438B (en) | Phlegm eliminating medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |